P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY

Detalles Bibliográficos
Autores principales: Soumerai, J. D., Jagadeesh, D., Salman, H., Samaniego, F., Patel, K., Stathis, A., Reddy, N., Kenkre, V. P., Asch, A., Diefenbach, C., Lossos, I. S., Persky, D., Awan, F., Huang, W., Vandever, K., Zelenetz, A. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430341/
http://dx.doi.org/10.1097/01.HS9.0000847324.06186.df

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430341/
http://dx.doi.org/10.1097/01.HS9.0000847324.06186.df

Ejemplares similares